Bispecific Antibodies in Non–Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration
- 1 June 2025
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 45 (3) , e472792
Abstract
Bispecific antibodies have ushered in a transformative era in treating non–small cell lung cancer (NSCLC), enabling dual-pathway targeting with promising clinical outcomes in previously refractory disease subsets. Recent US Food and Drug Administration approvals—including amivantamab, an epidermal growth factor receptor (EGFR)/mesenchymal-epithelial transition factor–targeting monoclonal antibody for EGFR exon 20 insertions and frontline EGFR-mutant (Exon 19 and 21) NSCLC, and zenocutuzumab for tumors harboring neuregulin 1 fusions—highlight their expanding therapeutic footprint. However, a new spectrum of on-target toxicities and implementation challenges are essential considerations as part of this innovation. This review dissects the evolving clinical data for bispecific antibodies in NSCLC, focusing on amivantamab, and provides a practical framework for managing dermatologic, infusion-related, and class-specific adverse events. We explore quality-of-life outcomes, financial toxicity, and the role of subcutaneous formulations in improving patient adherence and treatment experience. Furthermore, we highlight an emerging PD-1/vascular endothelial growth factor-A bispecific antibody (ivonescimab) and its potential to reshape frontline therapy paradigms in NSCLC. By integrating clinical trial evidence with real-world considerations, this review aims to equip oncologists with the tools to optimize the use of bispecific antibodies in NSCLC and guide future therapeutic integration.Keywords
This publication has 65 references indexed in Scilit:
- Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD‐1 and VEGF, in Chinese Patients With Advanced Solid TumorsCancer Medicine, 2025
- Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and SwitzerlandJAMA Health Forum, 2024
- Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR VariantJAMA, 2024
- Ivonescimab: First ApprovalDrugs, 2024
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyAnnals of Oncology, 2023
- Spectrum of Dermatologic Adverse Events Associated With Amivantamab UseJAMA Dermatology, 2023
- Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET InhibitorsTargeted Oncology, 2022
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆Annals of Oncology, 2021
- NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agentsAnnals of Oncology, 2020
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupportive Care in Cancer, 2011